Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083707 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00083707: Completed Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by University of Arkansas.
NCT00083707 is a Phase 2 study of Waldenstrom Macroglobulinemia that has completed, run by University of Arkansas. The registered enrollment target is 40 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083707, a Phase 2 study of Waldenstrom Macroglobulinemia, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/MIRT - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-01 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
What the finished NCT00083707 record still lists
NCT00083707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00083707 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00083707 about?
NCT00083707 is a clinical study titled "Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia". The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
What is the current status of trial NCT00083707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1999-01. Estimated completion is 2003-02.
What conditions does trial NCT00083707 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT00083707?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083707?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083707 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083707's enrollment target sits among peer trials
40 24th of 34 higher than 9 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia